Modality
Degrader
MOA
EGFRi
Target
GLP-1R
Pathway
Apoptosis
RA
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
~Jun 2017
→ ~Sep 2018
NDA/BLA
~Dec 2018
→ ~Mar 2020
Approved
Jun 2020
→ Aug 2028
ApprovedCurrent
NCT03575411
1,649 pts·RA
2020-06→2028-08·Active
1,649 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-08-072.4y awayPh3 Readout· RA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Active
Catalysts
Ph3 Readout
2028-08-07 · 2.4y away
RA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03575411 | Approved | RA | Active | 1649 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Mavuglumide | Bayer | Approved | GLP-1R |